Pacira Pharmaceuticals buy Royal Bank of Canada
Start price
03.08.23
/
50%
€34.80
Target price
03.08.24
€62.07
Performance (%)
-22.99%
Price
27.05.24
€26.80
Summary
This prediction is currently active. The prediction for Pacira Pharmaceuticals disappoints with a performance of -22.99%. This prediction currently runs until 03.08.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | -3.597% | -3.597% |
iShares Core DAX® | 0.192% | 3.121% |
iShares Nasdaq 100 | 1.245% | 5.051% |
iShares Nikkei 225® | -0.992% | 1.101% |
iShares S&P 500 | 0.154% | 2.864% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $70.00 to $68.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
01.03.24
01.03.24
€41.56
01.03.25
01.03.25
3.82%
27.05.24
27.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€28.40
03.11.23
03.11.23
€54.04
03.11.24
03.11.24
-3.52%
27.05.24
27.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€27.40
03.10.23
03.10.23
€65.04
03.10.24
03.10.24
-0.73%
27.05.24
27.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.00
01.03.23
01.03.23
€71.20
01.03.24
01.03.24
-34.50%
02.03.24
02.03.24